Table 1 LDCT in lung cancer screening
Trial Name | Study design | No. recruited | Characteristics of participants | Exsmoker quit (yrs) | Year started | Report date | LC baseline rate (LDCT) | Stage I Cancer at Baseline | ||
|---|---|---|---|---|---|---|---|---|---|---|
Age | Sex | Smoker(PkYr) | ||||||||
NLST [47] | LDCT vs CXR | 53454 | 55–74 | M/F | >=30 | <15 | 2002 | 2011 | 1.0% | 63.0% |
LDCT vs UC | 15822 | 50–75 | M/F | 15–18.75 | <10 | 2003 | 2016 | 0.9% | 63.9% | |
ITALUNG [39] | LDCT vs UC | 3206 | 55–69 | M/F | >=20 | <10 | 2004 | NR | 1.5% | 47.6% |
DEPISCAN [38] | LDCT vs CXR | 765 | 50–75 | M/F | >=15 | <15 | 2002 | 2006 | 2.38% | 0.9% |
LDCT vs UC | 2472 | 60–74 | M | >=20 | <10 | 2001 | 2007 | 2.2% | 57% | |
DLCST [97] | LDCT vs UC | 4104 | 50–70 | M/F | >=20 | <10 | 2004 | 2016 | 0.8% | 58.8% |
LDCT vs CXR | 3318 | 55–77 | M/F | >=30 | <10 | 2000 | 2005 | 1.9% | 53.3% | |